Raza Muhammad Zain, Nadeem Ali Ahmad, Khwaja Huzaifa Fayyaz, Omais Muhammad, Arshad Hafiz Muhammad Ehsan, Maqsood Musab
Department of Medicine, King Edward Medical University, Lahore, Punjab, Pakistan.
Department of Medicine, King Edward Medical University, Lahore, Punjab, Pakistan.
Ann Vasc Surg. 2025 Apr;113:95-111. doi: 10.1016/j.avsg.2024.12.079. Epub 2025 Jan 23.
Postembolization syndrome (PES), characterized by pain, fever, nausea, and vomiting, is a common but nonserious adverse event following arterial embolization, negatively impacting patient satisfaction with the procedure. This study aimed to evaluate the efficacy of dexamethasone-based prophylactic therapy in preventing PES, as well as to assess the effects of its dosage and timing of administration.
A systematic search was conducted across 3 databases, 2 trial registries, and citation searches to identify relevant studies. Data related to postoperative pain, fever, nausea, and vomiting were extracted and meta-analyzed using a random-effects model and the Mantel-Haenszel method. Meta-regression was performed to examine the role of dexamethasone dose and timing of administration as mediators.
Dexamethasone-based prophylactic therapy significantly reduced the risk of postoperative pain (risk ratio (RR) = 0.58, 95% confidence interval (CI): 0.48-0.69; P < 0.00001), fever (RR = 0.36, 95% CI: 0.22-0.61; P < 0.00001), nausea (RR = 0.52, 95% CI: 0.41-0.67; P < 0.00001), and vomiting (RR = 0.54, 95% CI: 0.36-0.82; P = 0.004) compared to placebo or no treatment. A higher dose of dexamethasone was associated with a significantly lower incidence of postoperative pain (P = 0.038). Regarding timing, postoperative and continuous (extending throughout the perioperative period) administration, was more effective than preoperative administration (P = 0.024; P = 0.007). A dosage of 6-12 mg was particularly effective in reducing the risk for all 4 symptoms.
Dexamethasone effectively prevents PES in patients undergoing arterial embolization. An optimal protocol may involve a divided dose regimen within the range of 6-12 mg, extending throughout the recovery period for maximum benefit.